ACKR3 and Familial prostate cancer: In an animal model of prostate cancer, coadministration of CCX771 (a CXCR7 inhibitor) and enzalutamide remarkably inhibited tumor growth and macrovascular formation, thus suppressing the drug resistance of enzalutamide.372